Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Novaliq

Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD
From Novaliq
Via Business Wire
Novaliq and Laboratoires Théa Announce Partnership and EU Approval for Vevizye® (Ciclosporin 0.1% Eye Drops Solution)
From Novaliq
Via Business Wire
Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease
From Novaliq
Via Business Wire
European Medicines Agency Accepts Novaliq’s Marketing Authorization Application for CyclASol® (ciclosporin ophthalmic solution) 0.1% for the Treatment of Dry Eye Disease
From Novaliq
Via Business Wire
Novaliq Announces Presentation of New Scientific Data on CyclASol® 0.1% (Cyclosporine Ophthalmic Solution) at the American Society of Cataract and Refractive Surgery Annual Meeting
From Novaliq
Via Business Wire
Novaliq Announces Publication of Second Pivotal Phase 3 Trial Data on CyclASol 0.1% (Cyclosporine Ophthalmic Solution) in JAMA Ophthalmology
From Novaliq
Via Business Wire
Novaliq Plans to File a Markting Authorisation Application for CyclASol® in the E.U. for the Treatment of Dry Eye Disease in July 2023
From Novaliq
Via Business Wire
Novaliq Announces FDA Acceptance of the New Drug Application for CyclASol® for the Treatment of Dry Eye Disease
From Novaliq
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.